Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Capricor Therapeutics Q2 2024 GAAP EPS $(0.35) Beats $(0.36) Estimate, Sales $3.971M Beat $3.664M Estimate

Author: Benzinga Newsdesk | August 07, 2024 04:58pm
Capricor Therapeutics (NASDAQ:CAPR) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.36) by 2.78 percent. The company reported quarterly sales of $3.971 million which beat the analyst consensus estimate of $3.664 million by 8.38 percent. This is a 1.38 percent increase over sales of $3.917 million the same period last year.

Posted In: CAPR


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist